The story so far.
German privately owned pharmaceutical company Boehringer Ingelheim said the Scottish Medicines Consortium (SMC) has accepted its blood-thinning drug Pradaxa for routine use in the National Health Service (NHS) of Scotland.
The drug prevents venous thromboembolic events in adults who have undergone total hip or knee replacement surgery, the company said.
The European Commission granted marketing authorisation for Pradaxa, which rivals Bayer AG.'s Xarelto and Bristol-Myers Squibb Co.'s apixaban, in all 27 EU member states in March 2008.
The company also said the Danish Institute for Rational Pharmacotherapy (IRF), which belongs to the Danish Medicines Agency, has endorsed Pradaxa as a good alternative to low molecular weight heparins (LMWH) both with respect to efficacy and ease of use.
Boehringer Ingelheim said it is still evaluating the efficacy and safety of Pradaxa to prevent strokes, to treat acute venous thromboembolic events and to prevent heart attacks in patients with acute coronary syndrome.
No comments:
Post a Comment